Synthetic lethality has been discovered for SHP2 inhibitors in BRAFV600E mutant CRCs [145], eventually translating into a phase 1b study where the allosteric inhibitor TNO155 is being tested in combination with the BRAF inhibitor dabrafenib in patients with advanced/metastatic BRAFV600E CRC (https://clinicaltrials.gov/ct2/show/NCT04294160?term=TNO155&draw=2&rank=5; accessed on 15 April 2021). This evidence concerns the gene BRAF and colorectal carcinoma.